Frequency of Vitamin B12 Deficiency in Type 2 Diabetic Patients Taking Metformin

Fraz Ahmed Baig, Saad Khan, Amber Rizwan

1. Internal Medicine, Nottingham University Hospitals, Nottingham, GBR 2. Internal Medicine, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, GBR 3. Family Medicine, Jinnah Post Graduate Medical Center, Karachi, PAK

Abstract

Introduction

Type 2 diabetes mellitus (DM) is a prevalent global health problem and is on a constant rise, especially in middle- and low-income countries. Vitamin B12 malabsorption is one of the reported side effects of metformin. Our study aims to assess the correlation of B12 deficiency in type 2 diabetics using metformin for their treatment.

Methods

This case-control study was conducted in a tertiary care hospital in Pakistan from February 2021 to December 2021. Patients (n=100) with a documented diagnosis of type 2 DM on metformin monotherapy for a minimum of six months were enrolled via consecutive convenient non-probability sampling. Another 100 patients without a history of diabetes were included in the study as a control group for comparison.

Results

Serum vitamin B-12 levels were higher in the non-diabetic participants as compared to the diabetic group (301.71 ± 72.12 vs. 189.25 ± 31.22; p-value: <0.0001). Hypovitaminosis was more significant in the diabetic group (p-value: 0.0000). Serum vitamin B12 levels were found to be declining with the increasing duration of metformin use (p-value: <0.0001).

Conclusion

Our study found a significant effect of vitamin B12 deficiency in metformin-treated patients. Therefore, it is prudent to recognize B12 deficiency as a potential side effect of long-term use of metformin. A periodic screening of B12 in such patients and subsequent supplementation of vitamin B12 is an effective and safe means of prevention of development or worsening of peripheral nerve damage and other clinical manifestations.

Materials And Methods
This case-control study was conducted in a tertiary care hospital in Pakistan from February 2021 to December 2021. Patients were enrolled via consecutive convenient non-probability sampling. Inclusion criteria for this study were patients with a documented diagnosis of type 2 DM between the ages of 20 to 60 years, of either gender, who were on metformin monotherapy for a minimum of six months. Pregnant, lactating women, vegans, and participants with diagnosed diabetic peripheral neuropathy were excluded from the study. The sample size was calculated by using statistical software OpenEpi (www.OpenEpi.com) with 80% power of the test and 95% confidence interval. Considering the 5.8% frequency of B12 deficiency in metformin users [5], the sample size calculated was 84. Considering dropping out, 100 patients were taken in the study. Another 100 patients without a history of diabetes were included in the study as a control group for comparison.

All the patients meeting the above-mentioned inclusion criteria were enrolled from the outpatient department of internal medicine after taking approval from the ethical review board of Jinnah Sindh Medical University (JSMU/IRB/2021-28C). The protocol risk was explained to the patient in detail. Informed consent was taken before each procedure and patients’ privacy and confidentiality were entertained. All the data was encrypted. Patients' demographics and other relevant information were recorded in self-structured questionnaires.

After registration, participants’ venous blood was taken via cubital blood and sent to the laboratory for vitamin B12 assay. All labs were taken in the morning to avoid the risk of diurnal variation. Vitamin B12 levels were measured by competitive-binding immunoenzymatic assays using a Unicel Dxi 800 analyzer (Beckman Coulter, Inc., Brea, USA). Participants were labeled as having vitamin B12 deficiency if their serum levels were less than 200 pg/mL [6].

All the data obtained was analyzed in Statistical Package for Social Science (SPSS), version 20 or above (IBM Corp., Armonk, USA). Mean and standard deviation were calculated for the age and serum B12 values. Frequency and percentages were calculated for the gender and frequency of vitamin B12-deficient participants. The mean age was compared using independent t-tests, while gender and other characteristics were compared using the Chi-square test. A p-value of less than 0.05 was considered significant.

**Results**

No statistically significant difference between the characteristics of the diabetic and non-diabetic groups was found upon age (p-value: 0.4330) and gender (p-value: 0.7718) comparison. Other factors including smoking, hypertension, and chronic kidney disease are also compared as follows (Table 1).

| Characteristics | Diabetes group (n=100) | Non-diabetes group (n=100) | p-value |
|-----------------|------------------------|-----------------------------|---------|
| Age (in years)  | 48 ± 09                | 47 ± 09                     | 0.4330  |
| Gender (%)      |                        |                             |         |
| Male            | 62                     | 60                          | 0.7718  |
| Female          | 38                     | 40                          |         |
| Other factors (%) |                      |                             |         |
| Smoking         | 22                     | 24                          | 0.7368  |
| HTN             | 31                     | 27                          | 0.5330  |
| CKD             | 09                     | 07                          | 0.6021  |

**TABLE 1: Demographics and risk factors of participants**

CKD: chronic kidney disease, HTN: hypertension

Serum vitamin B12 levels were higher in the non-diabetic participants as compared to the diabetic group (301.71 ± 72.12 vs. 189.25 ± 51.22; p-value: <0.0001). Hypovitaminosis was more significant in the diabetic group (p-value: 0.0000) (Table 2).
Characteristics

| Characteristics       | Diabetes group (n=100) | Non-diabetes group (n=100) | p-value |
|-----------------------|------------------------|-----------------------------|---------|
| Serum B-12 levels (pg/mL) | 189.25 ± 31.22         | 301.71 ± 72.12              | <0.0001 |
| Hypovitaminosis (%)   | 39                     | 12                          | 0.0000  |

**TABLE 2: Comparison of vitamin B12 levels between the diabetic and non-diabetic groups**

Serum vitamin B12 levels were found to be declining with the increasing duration of metformin use (p-value: <0.0001) (Table 3).

| Duration of metformin use | Serum B-12 levels (pg/mL) | p-value |
|---------------------------|---------------------------|---------|
| Less than 1 year (n=12)   | 231.82 ± 51.02            |         |
| Between 1 to 2 years (n=51)| 186.21 ± 28.34            | <0.0001 |
| More than 2 years (n=37)  | 161.61 ± 25.12            |         |

**TABLE 3: Correlation of duration of metformin use with serum B-12 levels**

pg/mL: picograms per milliliter

**Discussion**

Our study demonstrated that serum vitamin B12 levels were significantly lower in diabetics (189.25 ± 31.22) compared to non-diabetics (301.71 ± 72.12). Moreover, hypovitaminosis was considerably observed more in the non-diabetic group. The association between low vitamin B12 levels and metformin has been supported by numerous studies [7-9]. However, some contradictory studies state that there is no evidence providing the association between the two [10,11]. Upon further investigation, our study proved that with increasing duration of time, vitamin B12 levels were seen to drop. This finding has been anchored by high-level studies [9,12,13], due to which the 2017 American Diabetes Association treatment guidelines include keeping a regular check on vitamin B12 levels in diabetic patients using metformin [14].

The most possible explanation proposed for the role of metformin in lowering vitamin B12 levels is that it hinders the smooth functioning of the calcium-regulated membrane that helps in the absorption of the vitamin B12-intrinsic factor complex in the ileum [15]. This led to investigating whether the administration of multivitamin supplementation could help avoid this deficiency since minute quantities of vitamin B12 are present in supplements (2 to 30 ug/d). This was assessed in a retrospective study; it concluded that intake of vitamin supplements in patients taking metformin was seen to report fewer events of vitamin B12 deficiency (adjusted OR=0.14; 95% CI=0.04, 0.54) compared to the group that did not take multivitamins [16].

Our study bears a few limitations. We only assessed total vitamin B12 levels; however, holotranscobalamin II or methylmalonic acid could have been monitored since they accurately express vitamin B12 levels. Moreover, we did note the diet of the participants. Consequently, we could not rule out the possibility of other factors in significantly lowering vitamin B12. This points towards the fact that future studies should be conducted with a larger sample size to confirm the findings of our study.

**Conclusions**

Considering the rising prevalence of type 2 DM and the favorable safety and efficacy profile of metformin, its use as an insulin-sensitizing agent is widespread. Our study found a significant correlation between vitamin B12 deficiency in metformin-treated patients. Therefore, it is prudent to recognize B12 deficiency as a potential side effect of long-term use of metformin. A periodic screening of B12 in such patients and subsequent supplementation of vitamin B12 is an effective and safe means of prevention of development or worsening of peripheral nerve damage and other clinical manifestations.

**Additional Information**

**Disclosures**
Human subjects: Consent was obtained or waived by all participants in this study. Jinnah Sindh Medical University issued approval JSMU/IRB/2021-28C. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohrooge AW, Malanda B: IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018, 138:271-81. 10.1016/j.diabres.2018.02.023

2. Aamir AH, UI-Haq Z, Mahar SA, et al.: Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan. BMJ Open. 2019, 9:e025300. 10.1136/bmjopen-2018-025300

3. Marín-Peñalver JJ, Martín-Timón I, Sevillaño-Collantes C, Del Canizo-Gómez FI: Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016, 7:354-95. 10.4239/wjd.v7.i17.354

4. Strack T: Metformin: a review. Drugs Today (Barc). 2008, 44:305-14. 10.1358/dor.2008.44.4.1138124

5. Damiao CP, Rodrigues AO, Pinheiro MF, Cruz RA Filho, Cardoso GP, Taboada GF, Lima GA: Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. Sao Paulo Med J. 2016, 154:473-9. 10.1590/1516-3180.2015.01382111

6. Ankar A, Kumar A: Vitamin B12 deficiency. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2021.

7. Pflipsen MC, Oh RC, Sagul A, Seebusen DA, Seabquist D, Topolski R: The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med. 2009, 22:528-34. 10.3122/jabfm.2009.05.090044

8. de Jager J, Kooy A, Lebert P, et al.: Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010, 340:c2181. 10.1136/bmj.c2181

9. Wile DJ, Toth C: Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010, 33:156-61. 10.2337/dc09-0606

10. Raizada N, Jyotyuna VP, Sreevivas V, Tandon N: Serum vitamin B12 levels in type 2 diabetes patients on metformin compared to those never on metformin: a cross-sectional study. Indian J Endocrinol Metab. 2017, 21:424-8. 10.4103/ijem.IJEM_529_16

11. Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Gouverner ND: Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications. 2007, 21:118-23. 10.1016/j.jdiacomp.2005.10.005

12. Ko SH, Ko SH, Ahn YB, et al.: Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. J Korean Med Sci. 2014, 29:965-72. 10.3346/kjms.2014.29.7.965

13. Sato Y, Ouchi K, Funase Y, Yamauki K, Aizawa T: Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocr J. 2015, 60:1275-80. 10.1507/endocrj.ej15-0532

14. S. pharmacologic approaches to glycemic treatment. Diabetes Care. 2017, 40:S64-74. 10.2337/dci17-0011

15. Bauman WA, Shaw S, Jayahtileke E, Spungen AM, Herbert V: Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000, 23:1227-31. 10.2337/diacare.23.9.1227

16. Kanckerla V, Garn JV, Zakai NA, et al.: Multivitamin use and serum vitamin B12 concentrations in older-adult metformin users in REGARDS, 2003-2007. PLoS One. 2016, 11:e0160802. 10.1371/journal.pone.0160802